SEC Form 4 · accession 0001209191-15-040135
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martha J. Carter
Officer — See Remarks
Period of report
May 1, 2015
Accepted (ET)
May 7, 2015 · 5:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $23.61 | May 1, 2015 | A | 13,000 | A | — | May 1, 2025 | Common Stock | 13,000 | 13,000 | D |
| Restricted Stock UnitsF3,F4 | — | May 1, 2015 | A | 3,000 | A | — | — | Common Stock | 3,000 | 3,000 | D |
Explanation of responses
- F1The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant.
- F225% of the shares of common stock underlying this stock option award will vest on May 1, 2016, with the remaining 75% of the shares of common stock underlying this stock option award vesting thereafter in equal monthly installments through May 1, 2019, subject to the Reporting Person's continued employment with the Issuer.
- F3Each restricted stock unit represents a contingent right to receive one share of common stock.
- F4The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 1, 2016, 33.33% of the units vesting on May 1, 2017, and 33.33% of the units vesting on May 1, 2018, subject to the Reporting Person's continued employment with the Issuer.
Remarks
Chief Regulatory Officer and Senior Vice President